Literature DB >> 23302069

Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring.

Paul K L Chin, Murray L Barclay, Evan J Begg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23302069      PMCID： PMC3579270          DOI： 10.1111/j.1365-2125.2012.04408.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Interaction of chronic daily warfarin therapy and rifampin.

Authors:  R A O'Reilly
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

2.  Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.

Authors:  Thorsten Lehr; Sebastian Haertter; Karl-Heinz Liesenfeld; Alexander Staab; Andreas Clemens; Paul A Reilly; Jeffrey Friedman
Journal:  J Clin Pharmacol       Date:  2011-09-28       Impact factor: 3.126

Review 3.  Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Authors:  Menno V Huisman; Gregory Y H Lip; Hans-Christoph Diener; Martina Brueckmann; Joanne van Ryn; Andreas Clemens
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

Review 4.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

5.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Authors:  Sebastian Härtter; Michael Koenen-Bergmann; Ashish Sharma; Gerhard Nehmiz; Ute Lemke; Wolfgang Timmer; Paul A Reilly
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335
  5 in total
  3 in total

1.  Response to the letter by Dr Chin and co-workers.

Authors:  Sebastian Härtter; Michael Koenen-Bergmann; Ashish Sharma; Gerhard Nehmiz; Ute Lemke; Wolfgang Timmer; Paul A Reilly
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.

Authors:  Paul K L Chin; Daniel F B Wright; David M Patterson; Matthew P Doogue; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

3.  The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.

Authors:  Pascal Vranckx; Marco Valgimigli; Hein Heidbuchel
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.